NRs such as the GR (dexamethasone), RXR (bexarotene and alitretinoin), PPARα (fibrates), and PPARγ (thiazolidinediones) have already been successfully targeted by approved drugs for treating autoimmunity, cancer, hyperlipidemia, or type 2 diabetes, respectively. This evidence concerns the gene NR3C1 and hyperlipidemia.